ATI RN
ATI Pharmacology Proctored Exam
1. A provider prescribes phenobarbital for a client who has a seizure disorder. The medication has a long half-life of 4 days. How many times per day should the nurse expect to administer this medication?
- A. One
- B. Two
- C. Three
- D. Four
Correct answer: A
Rationale: Phenobarbital, with a long half-life of 4 days, remains at therapeutic levels in the body for an extended period. Due to this prolonged duration of action, the nurse should administer phenobarbital once a day to maintain a consistent therapeutic effect without the need for multiple daily doses. Administering the medication more than once a day would not be necessary and could increase the risk of side effects or toxicity. Therefore, the correct answer is to administer phenobarbital once a day.
2. A client has a new prescription for Enoxaparin. Which of the following instructions should the nurse include?
- A. Massage the injection site after administration.
- B. Aspirate before injecting the medication.
- C. Administer the medication into the abdomen.
- D. Administer the medication via intramuscular injection.
Correct answer: C
Rationale: The correct answer is to administer the medication into the abdomen. Enoxaparin is a medication that is administered subcutaneously, typically in the abdomen to ensure proper absorption. Massaging the injection site should be avoided as it can lead to bruising or bleeding under the skin. Aspirating before injecting the medication is not necessary for subcutaneous injections like Enoxaparin. Administering the medication via intramuscular injection is incorrect as Enoxaparin should be given subcutaneously.
3. A client has a new prescription for Sulfasalazine for the treatment of Crohn's disease. Which of the following instructions should the nurse include?
- A. Expect orange-yellow discoloration of urine and skin.
- B. Take the medication with food.
- C. Do not discontinue the medication if a sore throat occurs.
- D. Avoid prolonged exposure to sunlight.
Correct answer: A
Rationale: The correct answer is A: 'Expect orange-yellow discoloration of urine and skin.' Sulfasalazine can cause this harmless side effect, which does not require discontinuation of the medication. Option B is incorrect because Sulfasalazine is usually taken with food to minimize gastrointestinal side effects. Option C is incorrect as a sore throat is not a common reason to stop the medication. Option D is not directly related to the side effects of Sulfasalazine.
4. A healthcare professional is reviewing laboratory results for a client who is receiving heparin via continuous IV infusion. Which of the following results indicates that the heparin infusion should be increased?
- A. aPTT of 90 seconds
- B. Platelet count of 150,000/mm³
- C. INR of 1.0
- D. Hgb of 15 g/dL
Correct answer: A
Rationale: An aPTT of 90 seconds is above the therapeutic range for heparin, which typically falls between 60-80 seconds. This indicates that the current heparin dose is too high, and the infusion rate should be decreased to avoid excessive anticoagulation and the risk of bleeding. Monitoring aPTT is crucial in adjusting heparin therapy to maintain it within the therapeutic range.
5. A healthcare professional is preparing to administer Belimumab for a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare professional plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by slow IV infusion over the recommended time frame.
- C. Dilute the medication in an appropriate solution as per manufacturer guidelines.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: The correct action the healthcare professional should plan to take when administering Belimumab is to monitor the client for hypersensitivity reactions. Belimumab is known to cause severe infusion reactions, including anaphylaxis in some cases. Monitoring for hypersensitivity reactions is crucial to detect and manage any adverse reactions promptly. Options A, B, and C are incorrect because warming the medication, administering by slow IV infusion, and dilution are not specific actions needed for Belimumab administration. The priority is to monitor the client for potential hypersensitivity reactions to ensure their safety.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access